Tirzepatide, a novel incretin-based therapy for T2DM, showed robust HbA1c (−1.94%), FSG (−54.7 mg/dl), and body weight (−8.5 kg) reductions, without an increased risk of hypoglycemia. This evidence concerns the gene GCG and type 2 diabetes mellitus.